Provided by Tiger Trade Technology Pte. Ltd.

Rallybio Corp.

8.87
-0.2200-2.42%
Post-market: 8.870.00000.00%17:03 EDT
Volume:145.80K
Turnover:1.34M
Market Cap:46.84M
PE:-5.58
High:9.47
Open:9.00
Low:8.87
Close:9.09
52wk High:11.49
52wk Low:1.76
Shares:5.28M
Float Shares:2.54M
Volume Ratio:1.06
T/O Rate:5.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5900
EPS(LYR):-1.5948
ROE:-15.01%
ROA:-30.07%
PB:0.81
PE(LYR):-5.56

Loading ...

Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization

TIPRANKS
·
Mar 18

Rallybio FY2025 net loss narrowed 84.46% to USD 8.98 million

Reuters
·
Mar 17

Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves

TIPRANKS
·
Mar 07

Rallybio in Reverse Merger With Candid Therapeutics

Dow Jones
·
Mar 02

BRIEF-Rallybio Corporation And Candid Therapeutics Announce Merger Agreement

Reuters
·
Mar 02

Rallybio Corp - Combined Company to Operate as Candid Therapeutics Under Ticker Cdrx

THOMSON REUTERS
·
Mar 02

Rallybio Corp - Candid Secures Oversubscribed and Upsized Private Financing of Over $505 Mln in Gross Proceeds

THOMSON REUTERS
·
Mar 02

Rallybio Corp - Co's Equityholders to Own 3.65% of Combined Company

THOMSON REUTERS
·
Mar 02

Rallybio Corp: Pre-Transaction Rallybio Equityholders Are Expected to Own Approximately 3.65% of Combined Co

THOMSON REUTERS
·
Mar 02

Rallybio Corp - Over $505 Mln Financing Committed by Investors

THOMSON REUTERS
·
Mar 02

Rallybio Corp - Ken Song to Lead Combined Company as CEO

THOMSON REUTERS
·
Mar 02

Rallybio Corp - Pro-Forma Cash of About $700 Mln Expected at Closing

THOMSON REUTERS
·
Mar 02

Rallybio Corp: Combined Company's Cash Balance at Closing Is Expected to Fund Operations Through 2030

THOMSON REUTERS
·
Mar 02

Press Release: Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Dow Jones
·
Mar 02

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM

Reuters
·
Mar 02

Rallybio’s RLYB116 Clears Phase 1 Milestone, Sharpening Its Autoimmune Pipeline

TIPRANKS
·
Feb 28

Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Benzinga
·
Feb 17

BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 Study

Reuters
·
Feb 17

Rallybio Reports Positive Phase 1 Results for RLYB116 in Complement-Mediated Diseases

Reuters
·
Feb 17

Rallybio Corp - Rlyb116 Phase 2 Trial Planned for 2H 2026 With Potential for Topline Data in 2027

THOMSON REUTERS
·
Feb 17